Drugs / Vinorelbine
last change 11 days ago re-read 9 days ago

Vinorelbine

Small molecule

Developed for
breast cancer · non-small cell lung carcinoma · lung cancer · HER2 positive breast carcinoma · female breast carcinoma · lymphoma · Her2-receptor negative breast cancer · prostate cancer
+107 more · triple-negative breast carcinoma · Hodgkins lymphoma · breast neoplasm · rhabdomyosarcoma · breast carcinoma · classic Hodgkin lymphoma · malignant pleural mesothelioma · sarcoma · cancer · metastatic malignant neoplasm in the brain · neoplasm · anaplastic large cell lymphoma · cancer of unknown primary site · cervical cancer · estrogen-receptor positive breast cancer · lung adenocarcinoma · metastatic neoplasm · non-Hodgkin lymphoma · ovarian cancer · ovarian carcinoma · small cell lung carcinoma · alveolar rhabdomyosarcoma · botryoid rhabdomyosarcoma · childhood malignant neoplasm · diffuse large B-cell lymphoma · fallopian tube cancer · hormone receptor-positive breast cancer · low grade glioma · lung large cell carcinoma · male breast carcinoma · neuroblastoma · progesterone-receptor positive breast cancer · prostate carcinoma · soft tissue sarcoma · spindle cell rhabdomyosarcoma · adrenal cortex carcinoma · aggressive B-cell non-Hodgkin lymphoma · breast carcinoma by gene expression profile · carcinoid tumor · carcinoma · central nervous system neoplasm · cervical adenosquamous carcinoma · cervical carcinoma · colon carcinoma · cutaneous melanoma · cutaneous neuroendocrine carcinoma · endometrial cancer · endometrial carcinoma · esophageal cancer · esophageal squamous cell carcinoma · estrogen-receptor negative breast cancer · Ewing sarcoma · gastric cancer · head and neck cancer · head and neck neoplasm · head and neck squamous cell carcinoma · hereditary breast carcinoma · hereditary pheochromocytoma-paraganglioma · Hodgkin's lymphoma, lymphocytic depletion · Hodgkin's lymphoma, mixed cellularity · invasive ductal breast carcinoma · kidney cancer · leukemia · lung carcinoma · lung neoplasm · malignant leptomeningeal tumor · malignant mesothelioma · mature T-cell and NK-cell non-Hodgkin lymphoma · medullary thyroid gland carcinoma · medulloblastoma · metastatic malignant neoplasm · metastatic melanoma · nodular lymphocyte predominant Hodgkin lymphoma · nodular sclerosis classical Hodgkin lymphoma · osteosarcoma · ovarian germ cell tumor · pancreatic ductal adenocarcinoma · pancreatic endocrine carcinoma · pancreatic large cell neuroendocrine carcinoma · paraganglioma · pheochromocytoma · plasma cell myeloma · PPoma · primary mediastinal large B-cell lymphoma · primary peritoneal carcinoma · progesterone-receptor negative breast cancer · refractory malignant neoplasm · renal cell carcinoma · salivary gland adenoid cystic carcinoma · salivary gland carcinoma · secondary malignant neoplasm · squamous cell carcinoma · urinary bladder cancer · uterine corpus sarcoma · vaginal cancer · Wilms tumor · amyloidosis · BRCA1-related cancer predisposition · BRCA2-related cancer predisposition · colon adenocarcinoma · desmoid tumor · malignant epithelial tumor of ovary · mesothelioma · nasopharyngeal carcinoma · pleural mesothelioma · rectum adenocarcinoma · small cell carcinoma
Investigated by
National Cancer Institute (NCI) · Fudan University · GlaxoSmithKline · Eli Lilly and Company · University Hospital of Crete · Hellenic Oncology Research Group
+277 more · Pierre Fabre Laboratories · Sanofi · Sun Yat-sen University · Brigham and Women's Hospital · Children's Oncology Group · Genentech, Inc. · SWOG Cancer Research Network · Alliance for Clinical Trials in Oncology · Boehringer Ingelheim · Cancer Institute and Hospital, Chinese Academy of Medical Sciences · Hoffmann-La Roche · Massachusetts General Hospital · Novartis Pharmaceuticals · University of Washington · Amgen · AstraZeneca · Chinese Academy of Medical Sciences · Dana-Farber Cancer Institute · Memorial Sloan Kettering Cancer Center · National Cancer Institute, Naples · Pierre Fabre Laboratories · Beth Israel Deaconess Medical Center · Bristol-Myers Squibb · European Organisation for Research and Treatment of Cancer - EORTC · H. Lee Moffitt Cancer Center and Research Institute · Medical Research Council · Northwestern University · Roche Pharma AG · iOMEDICO AG · AIO-Studien-gGmbH · Arbeitsgemeinschaft fur Internistische Onkologie · Aventis Pharmaceuticals · Celgene Corporation · Children's Cancer Group, China · Gustave Roussy, Cancer Campus, Grand Paris · National Cancer Centre, Singapore · National Cancer Institute, France · Pfizer · Pierre Fabre Pharma GmbH · Shandong Cancer Hospital and Institute · Swiss Cancer Institute · The First Affiliated Hospital with Nanjing Medical University · UNC Lineberger Comprehensive Cancer Center · University of Miami · Zhiyong Yu · Arbeitskreis Klinische Studien · Assistance Publique Hopitaux De Marseille · Baili-Bio (Chengdu) Pharmaceutical Co., Ltd. · Bayside Health · Case Comprehensive Cancer Center · City of Hope Medical Center · European Institute of Oncology · French Innovative Leukemia Organisation · GBG Forschungs GmbH · Gynecologic Oncology Group · Henan Cancer Hospital · IRCCS Azienda Ospedaliera Universitaria San Martino - IST Istituto Nazionale per la Ricerca sul Cancro, Genoa, Italy · Istituto Nazionale per lo Studio e la Cura dei Tumori · Istituto Romagnolo per lo Studio dei Tumori Dino Amadori IRST S.r.l. IRCCS · Liaoning Cancer Hospital & Institute · NCIC Clinical Trials Group · National Taiwan University Hospital · Puma Biotechnology, Inc. · SCRI Development Innovations, LLC · SOLTI Breast Cancer Research Group · Seagen Inc. · Seoul National University Hospital · Sichuan Baili Pharmaceutical Co., Ltd. · Spanish Breast Cancer Research Group · Susan G. Komen Breast Cancer Foundation · Tianjin Medical University Cancer Institute and Hospital · UNICANCER · University Hospital, Brest · University of Chicago · all 283 on the full record

Regulatory milestones approvals, filings & regulatory actions · 3 recorded

MilestoneJurisdictionBrandIndicationDateSentence it was read from
Label expansions (2) US (FDA) NAVELBINE — 2001-10-02 – 2002-11-05 fda.gov ↗
Approved US (FDA) NAVELBINE — 1994-12-23 fda.gov ↗

Trials 318 · started per year

today
US approved 1994
2
1
5
10
12
11
17
10
15
13
14
12
11
19
10
13
11
13
1
3
7
13
14
10
11
8
9
6
12
14
6
3
1995199619971998199920002001200220032004200520062007200820092010201120122013201420152016201720182019202020212022202320242025202620272028
PhaseRegistry idDatesIndicationSponsorStatusOutcome
Phase 03 trials · 1 met primary
Phase 0 NCT05553782 Nov 2023 → Apr 2029 expected head and neck squamous cell carcinoma, salivary gland adenoid cystic carcinoma Brigham and Women's Hospital Recruiting No outcome recorded
Phase 0 NCT05238831 Jan 2023 → May 2026 female breast carcinoma, ovarian carcinoma, pancreatic ductal adenocarcinoma, pancreatic large cell neuroendocrine carcinoma +2 OHSU Knight Cancer Institute Withdrawn No outcome recorded
Phase 0 NCT02802748 Jul 2016 → Jan 2018 breast cancer SOLTI Breast Cancer Research Group Completed Met primary
Phase 130 trials
Phase 1 NCT06137651 Dec 2023 → Mar 2024 breast carcinoma, malignant leptomeningeal tumor, metastatic malignant neoplasm in the brain Northwestern University Withdrawn No outcome recorded
Phase 1 NCT02897986 Jan 2017 → Jan 2020 childhood malignant neoplasm Assistance Publique Hopitaux De Marseille Unknown No outcome recorded
Phase 1 NCT02892123 Sep 2016 → Oct 2024 HER2 positive breast carcinoma Jazz Pharmaceuticals Completed No outcome recorded
Phase 1 NCT02555007 Aug 2015 → Jul 2018 malignant pleural mesothelioma, non-small cell lung carcinoma Assistance Publique Hopitaux De Marseille Completed No outcome recorded
Phase 1 NCT01214616 Oct 2010 → May 2013 neoplasm Boehringer Ingelheim Completed No outcome recorded
Phase 1 NCT01238029 Oct 2010 → Jul 2014 HER2 positive breast carcinoma Sponsor GmbH Terminated No outcome recorded
Phase 1 NCT01155258 Jun 2010 → Jan 2013 PPoma, carcinoid tumor, cervical carcinoma, cutaneous neuroendocrine carcinoma +14 University of Southern California Completed No outcome recorded
Phase 1 NCT01060514 Feb 2010 → Feb 2012 breast cancer, non-small cell lung carcinoma Northwestern University Terminated No outcome recorded Stop: Enrollment
Phase 1 NCT00958724 Jul 2009 → Apr 2010 cancer Puma Biotechnology, Inc. Completed No outcome recorded
Phase 1 NCT00906698 Jun 2009 → Jan 2013 neoplasm Boehringer Ingelheim Completed No outcome recorded
Phase 1/224 trials · 1 missed
Phase 1/2 NCT06202261 Apr 2023 → Dec 2026 expected breast carcinoma Chia Tai Tianqing Pharmaceutical Group Co., Ltd. Recruiting No outcome recorded
Phase 1/2 NCT04625907 Sep 2020 → Jun 2030 expected rhabdomyosarcoma University of Birmingham Recruiting No outcome recorded
Phase 1/2 NCT03518606 Jun 2018 → Apr 2022 breast cancer, cervical cancer, head and neck cancer, prostate cancer UNICANCER Completed No outcome recorded
Phase 1/2 NCT02925000 Jun 2017 → Oct 2020 cancer Taiwan Liposome Company Completed No outcome recorded
Phase 1/2 NCT03346642 May 2017 → Mar 2019 primary mediastinal large B-cell lymphoma Chinese PLA General Hospital Unknown No outcome recorded
Phase 1/2 NCT02658084 Apr 2017 → Oct 2018 breast cancer University of Miami Terminated No outcome recorded Stop: Enrollment
Phase 1/2 NCT02813135 Aug 2016 → Feb 2031 expected childhood malignant neoplasm Gustave Roussy, Cancer Campus, Grand Paris Recruiting No outcome recorded
Phase 1/2 NCT02331251 Dec 2014 → Jan 2018 breast cancer, cancer of unknown primary site, ovarian carcinoma, pancreatic adenocarcinoma +2 Western Regional Medical Center Terminated Missed primary
Phase 1/2 NCT00912275 Nov 2008 → Mar 2015 breast cancer National Taiwan University Hospital Completed No outcome recorded
Phase 1/2 NCT00828074 Nov 2008 → Apr 2014 female breast carcinoma City of Hope Medical Center Completed No outcome recorded
Phase 2189 trials · 5 met primary · 10 missed
Phase 2 NCT07021989 Jul 2026 → May 2029 expected classic Hodgkin lymphoma Michael Spinner, MD Not yet recruiting No outcome recorded
Phase 2 NCT07657130 Jul 2025 → Jun 2026 overdue female breast carcinoma Liaoning Cancer Hospital & Institute Recruiting No outcome recorded
Phase 2 NCT06690840 Mar 2025 → Dec 2026 expected triple-negative breast carcinoma European Institute of Oncology Recruiting No outcome recorded
Phase 2 NCT06839560 Mar 2025 → Sep 2028 expected metastatic malignant neoplasm in the brain Cancer Institute and Hospital, Chinese Academy of Medical Sciences Recruiting No outcome recorded
Phase 2 NCT06816771 Feb → Dec 2025 overdue rhabdomyosarcoma Shandong Cancer Hospital and Institute Recruiting No outcome recorded
Phase 2 NCT06692491 Jan 2025 → Dec 2027 expected — Peking University Shenzhen Hospital Not yet recruiting No outcome recorded
Phase 2 NCT06653972 Nov 2024 → Feb 2026 overdue Her2-receptor negative breast cancer Wang Jiayu Not yet recruiting No outcome recorded
Phase 2 NCT06533722 Aug → Sep 2024 Her2-receptor negative breast cancer Sun Yat-sen University Completed No outcome recorded
Phase 2 NCT06416930 Jun 2024 → Jun 2027 expected malignant pleural mesothelioma Cancer Institute and Hospital, Chinese Academy of Medical Sciences Not yet recruiting No outcome recorded
Phase 2 NCT06377566 Apr 2024 → Apr 2027 expected Hodgkins lymphoma Memorial Sloan Kettering Cancer Center Recruiting No outcome recorded
Show all 189 trials opens the full record — a long page
Phase 2/33 trials
Phase 2/3 NCT03423849 Feb 2018 → Feb 2020 breast cancer Zhiyong Yu Unknown No outcome recorded
Phase 2/3 NCT00253591 Jun 2005 → Dec 2007 lung cancer Medical Research Council Completed No outcome recorded
Phase 2/3 NCT00049660 Sep 2002 → Dec 2004 female breast carcinoma European Organisation for Research and Treatment of Cancer - EORTC Terminated No outcome recorded Stop: Enrollment
Phase 355 trials · 7 met primary · 9 missed
Phase 3 NCT07466316 Jun 2026 → Mar 2031 expected rhabdomyosarcoma Children's Oncology Group Not yet recruiting No outcome recorded
Phase 3 NCT07088263 Sep 2025 → Jul 2027 expected breast neoplasm Sun Yat-sen University Recruiting No outcome recorded
Phase 3 NCT06632327 Dec 2024 → Apr 2029 expected non-small cell lung carcinoma Alliance for Clinical Trials in Oncology Active not recruiting No outcome recorded
Phase 3 NCT06382142 Jun 2024 → Jun 2026 overdue triple-negative breast carcinoma Sichuan Baili Pharmaceutical Co., Ltd. Active not recruiting Met primary
Phase 3 NCT07450508 Apr → Oct 2024 classic Hodgkin lymphoma Cairo University Completed No outcome recorded
Phase 3 NCT06343948 Apr 2024 → May 2026 overdue hormone receptor-positive breast cancer Sichuan Baili Pharmaceutical Co., Ltd. Active not recruiting Met primary
Phase 3 NCT06072612 Dec 2023 → Dec 2027 expected breast cancer BriaCell Therapeutics Corporation Recruiting No outcome recorded
Phase 3 NCT05954442 Sep 2023 → Aug 2025 overdue triple-negative breast carcinoma Fudan University Recruiting No outcome recorded
Phase 3 NCT05711628 Aug 2023 → Jun 2028 classic Hodgkin lymphoma National Cancer Institute (NCI) Withdrawn No outcome recorded
Phase 3 NCT05347134 Jun 2022 → Nov 2023 overdue triple-negative breast carcinoma Sichuan Kelun-Biotech Biopharmaceutical Co., Ltd. Active not recruiting Met primary
Phase 45 trials
Phase 4 NCT05131841 Jan 2021 → Dec 2022 breast cancer Zhejiang Cancer Hospital Unknown No outcome recorded
Phase 4 NCT03355157 Mar 2018 → Aug 2024 breast cancer GBG Forschungs GmbH Completed No outcome recorded
Phase 4 NCT03270007 Nov 2017 → Jun 2024 breast cancer Tao OUYANG Unknown No outcome recorded
Phase 4 NCT01848613 Oct 2012 → Oct 2016 non-small cell lung carcinoma Istituto Romagnolo per lo Studio dei Tumori Dino Amadori IRST S.r.l. IRCCS Completed No outcome recorded
Phase 4 NCT00372476 Jun 2006 → Jul 2012 breast cancer Novartis Pharmaceuticals Completed No outcome recorded
Phase not applicable8 trials · 2 missed
— NCT07589972 Apr 2026 → Dec 2027 expected breast carcinoma by gene expression profile Tianjin Medical University Cancer Institute and Hospital Not yet recruiting No outcome recorded
— NCT06576635 Dec 2024 → Sep 2026 overdue non-small cell lung carcinoma University of Illinois at Chicago Recruiting No outcome recorded
— NCT06211881 Oct 2023 → Sep 2025 mature T-cell and NK-cell non-Hodgkin lymphoma The First Affiliated Hospital with Nanjing Medical University Unknown No outcome recorded
— NCT06015126 Oct 2022 → Jan 2025 breast cancer Yan Xue Unknown No outcome recorded
— NCT03947242 Jun 2019 → Jun 2020 HER2 positive breast carcinoma Henan Cancer Hospital Unknown No outcome recorded
— NCT00864266 Mar 2009 → Jun 2020 non-small cell lung carcinoma European Lung Cancer Working Party Completed Missed primary
— NCT00675597 May 2008 → Feb 2012 lung cancer Memorial Sloan Kettering Cancer Center Completed No outcome recorded
— NCT00003730 Dec 1998 → Nov 2004 female breast carcinoma European Organisation for Research and Treatment of Cancer - EORTC Completed Missed primary
Phase not stated1 trial
— NCT02985658 — hereditary breast carcinoma, triple-negative breast carcinoma University of Washington No longer available No outcome recorded
Comparator or background therapy187 trials
Phase 1 NCT05299164 Background May 2022 → Dec 2023 overdue non-Hodgkin lymphoma Institute of Hematology & Blood Diseases Hospital, China Active not recruiting No outcome recorded
Phase 1 NCT04648033 Background Dec 2020 → Oct 2023 non-small cell lung carcinoma University of Oxford Completed No outcome recorded
Phase 1 NCT04398108 Background Aug 2020 → Apr 2021 HER2 positive breast carcinoma Zai Lab (Shanghai) Co., Ltd. Completed No outcome recorded
Phase 1 NCT04299113 Background May 2020 → Dec 2026 expected rhabdomyosarcoma Jonsson Comprehensive Cancer Center Active not recruiting No outcome recorded
Phase 1 NCT01684111 Background Jun 2013 → Jan 2016 non-small cell lung carcinoma Aktion Bronchialkarzinom e.V. Completed No outcome recorded
Show all 187 trials opens the full record — a long page

News releases announcing trial results or a regulatory action · 3

DateIssuerRelease
2018-04-16 CSPC ZhongQi Pharmaceutical Technology Co., Ltd. Regulatory VOLUNTARY ANNOUNCEMENT - "VINORELBINE TARTRATE LIPOSOME INJECTION" FOR THE TREATMENT OF LUNG CANCER WAS GRANTED CLINICAL TRIAL APPROVAL irasia.com ↗
“VINORELBINE TARTRATE LIPOSOME INJECTION” FOR THE TREATMENT OF LUNG CANCER WAS GRANTED CLINICAL TRIAL APPROVAL
2016-08-05 Eisai Inc. Results CHINA FOOD AND DRUG ADMINISTRATION ACCEPTS NDA FOR ANTICANCER AGENT HALAVEN® eisai.com ↗
From the results for the study, eribulin demonstrated a statistically significant extension in PFS over the comparator treatment vinorelbine.
2016-05-13 Eisai Inc. Results ANTICANCER AGENT HALAVEN® DEMONSTRATES STATISTICALLY SIGNIFICANT EXTENSION IN PROGRESSION FREE SURVIVAL COMPARED TO VINORELBINE IN PHASE Ⅲ CLINICAL STUDY OF PATIENTS WITH BREAST CANCER IN CHINA eisai.com ↗
eribulin demonstrated a statistically significant extension in the study's primary endpoint of progression free survival (PFS) over the comparator treatment vinorelbine.

Evidence & citations 22 cited values

Every value below carries the sentence it was read from. 509 sources stand behind the page.

FieldValueCited text
Known as Vinorelbine “including but not limited to DHAP (dexamethasone, cisplatin, high-dose cytarabine), ESHAP (etoposide, methylprednisolone, high-dose cytarabine and cisplatin), DICE...” NCT04486391 ↗
488

“Any of the following single-agent chemotherapy may be given at the discretion of the investigator, with a cycle length not to exceed four weeks: Capecitabine, Vinorelbine,...” NCT01156753 ↗

“Participants will receive 6 cycles of a standard intravenous or oral chemotherapy regimen or an Antibody-Drug Conjugate (ADC), selected by the investigator from...” NCT07371910 ↗

“Drugs may include all or a subset of the following which each may be tested as single agents or in any number of combinations including, but not limited to: Lenvatinib,...” NCT05553782 ↗

“Patients in the TPC arm of the study will be treated with one or a combination of the following: carboplatin, taxanes, capecitabine, gemcitabine, vinorelbine or eribulin in...” NCT06072612 ↗

“In the Tailored chemotherapy arm, 7 different combination chemotherapy regimens that containing 2 drugs among taxotere, epirubicin, cisplatin, vinorelbine, and 5FU, will be...” NCT00776724 ↗

“The study is aimed to evaluate the efficacy of investigator's choice (ICC) of chemotherapy (nab-paclitaxel, capecitabine, eribulin, carboplatin, vinorelbine, or utidelone)...” NCT05954442 ↗

“Induction treatment: 2 cyles of Q3W second-line plantium-based chemotherapy according to standard of care: Cisplatin or carboplatin in combination with pemetrexed, paclitaxel,...” NCT05383001 ↗

“Carboplatin, cisplatin, paclitaxel, docetaxel, gemcitabine, vinorelbine, pemetrexed, or erlotinib administered on Day 1 of every 21-day cycle except gemcitabine, which was...” NCT00312728 ↗

“patient will receive 2 cycles of cisplatine 80 mg/m² at day 29 and day 50 more vinorelbine 15 mg/m² at day 29, day 36 and day 50 and 57 associated to cetuximab 400 mg/m² at...” NCT00985855 ↗

“Participants will receive investigator's choice of chemotherapy determined prior to randomization from 1 of the 4 allowed regimens as per protocol: eribulin, or vinorelbine or...” NCT07556848 ↗

Show 478 more sources

Known as Navelbine “This clinical trail will combine the chemotherapy drugs, Estramustine and Vinorelbine (Navelbine), on an intermittent therapy strategy based on PSA response in the treatment of...” NCT00151086 ↗
17

“A Randomized Phase III Study of Trastuzumab (Herceptin) in Combination With Either Vinorelbine (Navelbine), or Taxane-based Chemotherapy in Patients With HER2 Overexpressing...” NCT00146549 ↗

“Vinorelbine (trade name Navelbine) is an anti-mitotic chemotherapy drug that is given as a treatment for some types of cancer, including breast cancer and non-small cell lung cancer.” NCT00014430 ↗

“Vinorelbine(Navelbine) is a third-line treatment option for Hodgkin's disease(HD) after transplantation failed, while both HD and ALCL express CD30.” NCT03443128 ↗

“Vinorelbine(Navelbine) is a third-line treatment option for Hodgkin's disease(HD) after transplantation failed, while both HD and ALCL express CD30.” NCT03397953 ↗

“Vinorelbine tartrate soft capsule (also named Navelbine; registration No. H20140657; Pierre Fabre Medicament, Boulogne, France) 40 mg once orally” NCT03932526 ↗

“They will receive one of the following drugs with tariquidar: doxorubicin (Adriamycin ), vinorelbine (Navelbine ), or docetaxel (Taxotere ).” NCT00011414 ↗

“A Phase I Absolute Bioavailability Study of Oral NAVELBINE (Vinorelbine Tartrate) in Patients With Solid Tumors” NCT00006088 ↗

“adjuvant chemotherapy with Xeloda (capecitabine), Methotrexate and Navelbine (vinorelbine tartrate) (XMN).” NCT00194779 ↗

“administration of a propranolol (HEMANGIOL®) and oral metronomic vinorelbine (NAVELBINE®) combination” NCT02897986 ↗

“Vinorelbine (Navelbine®): 25-30 mg/m2 on days 1 and 8 of a 21-day cycle” NCT02492711 ↗

Show 7 more sources

Known as Navelbine oral “Oral Vinorelbine (Navelbine oral) 50 mg 3 times weekly, monday, wednesday and friday plus Capecitabine (Xeloda) 1000 mg/m2 2 times daily day 1-14 in a 3 weekly schedule.” NCT01941771 ↗
Known as NSC-608210 “Docetaxel (NSC-628503) And Vinorelbine (NSC-608210) Plus Filgrastim (NSC-614629) With Weekly Trastuzumab (NSC-688097) For HER-2 Positive, Stage IV Breast Cancer” NCT00041067 ↗
Known as Oral Vinorelbine Tartrate “Drug: Oral Vinorelbine Tartrate” NCT05823623 ↗
Known as TLC178 ClinicalTrials.gov intervention name — accepted as the source's own label NCT02925000 ↗
Known as Vin “Vinorelbine (Vin) will be administered at a dose of 25 mg/m\^2 as intravenous infusion on Days 1 and 8.” NCT00842712 ↗
1

“gemcitabine (Gem) with vinorelbine (Vin), etoposide (Eto), cisplatin (Cis), or carboplatin (Car).” PMID 22031232 ↗ Jan 2012

Known as Vinorelbin “Vinorelbin: i.v. 25 mg/ m² d1, d8, d15 3qw until progress” NCT01520103 ↗
Known as Vinorelbine (Navelbine oral) “Vinorelbine (Navelbine oral)” NCT01941771 ↗
Known as Vinorelbine (Vino) “Vinorelbine (Vino)” NCT03262935 ↗
Known as Vinorelbine ditartrate “Patients receive oral vinorelbine ditartrate once daily on days 1 and 8 and oral prednisone once daily on days 1-21.” NCT00627354 ↗
4

“vinorelbine (vinorelbine ditartrate)” NCT01104259 ↗

“Drug: Vinorelbine ditartrate” NCT00354393 ↗

NCT00266110 ↗

NCT01155258 ↗

Known as vinorelbine tartrate “An Open-Label Phase II Study of Navelbine (Vinorelbine Tartrate) and Taxotere (Docetaxel) as First-Line Therapy for Metastatic Breast Cancer” NCT00006682 ↗
34

“Patients receive vinorelbine tartrate IV over 6-10 minutes and gemcitabine hydrochloride IV over 100 minutes on days 1 and 8.” NCT00070304 ↗

“Patients receive ifosfamide IV over 24 hours on days 1-4 and vinorelbine tartrate IV over 6-10 minutes on days 1 and 5.” NCT00006760 ↗

“A Phase I Absolute Bioavailability Study of Oral NAVELBINE (Vinorelbine Tartrate) in Patients With Solid Tumors” NCT00006088 ↗

“Vinorelbine tartrate injection, 25 \~ 30 mg/m2 each time, intravenous drip” NCT05420779 ↗

“vinorelbine tartrate IV over 6-10 minutes on days 1, 8, and 15” NCT00194779 ↗

“vinorelbine (vinorelbine tartrate)” NCT00337194 ↗

“Vinorelbine Tartrate (Navelbine)” NCT00675597 ↗

“Vinorelbine tartrate injection” NCT06079983 ↗

“Vinorelbine Tartrate Injection” NCT07533123 ↗

“Drug: vinorelbine tartrate” NCT00863512 ↗

Show 24 more sources

Known as Vinorelbine tartrate (Navelbine) “Vinorelbine tartrate (Navelbine)” NCT00659269 ↗
Known as Vinorelbine: Navelbine “- Vinorelbine, Navelbine” NCT01220284 ↗
1

“Vinorelbine: Navelbine” NCT01802970 ↗

Known as Vinorelbine: Navelbine,vinorelbine bitartrate injection “Vinorelbine: Navelbine,vinorelbine bitartrate injection” NCT02223611 ↗
Known as Vinorelbine: Sandoz vinorelbine “Vinorelbine: Sandoz vinorelbine” NCT01648517 ↗
Known as VNB “oral metronomic vinorelbine (VNB) and letrozole versus either treatment alone in postmenopausal women with newly diagnosed untreated HR+ and HER2-negative, stage I-III operable...” NCT02802748 ↗
Known as VNR “oral vinorelbine (VNR)” PMID 37402471 ↗ Jul 2023
Known as VRL “metronomic oral vinorelbine (VRL; 30 mg/day)” PMID 33743073 ↗ Mar 2021
Action Inhibit “vinorelbine, work in different ways to stop the growth of tumor cells” NCT00103233 ↗
Modality Small molecule “vinorelbine, a semi-synthetic vinca alkaloid” PMID 19533657 ↗ Oct 2009
Route Intravenous “vinorelbine IV over 6-10 minutes” NCT00002813 ↗